Clinical trial
Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After…
NCT00356525 · Eli Lilly and Company, Industry · Terminated
Key facts
| NCT number | NCT00356525 |
|---|---|
| Title | Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor |
| Official title | Phase II, Randomized, Open-Label Trial of Biweekly Pemetrexed Plus Gemcitabine vs. Pemetrexed or Pemetrexed Plus Carboplatin in Relapsed Non Small Cell Lung Cancer After Neoadjuvant or Adjuvant Chemotherapy |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Neoplasms |
| Intervention type | Drug |
| Interventions | pemetrexed, gemcitabine, carboplatin, Pemetrexed |
| Enrollment | 41 |
| Start date | Sep 1, 2006 |
| Primary completion | Jun 1, 2008 |
| Completion | Apr 1, 2009 |
| First posted | Jul 26, 2006 |
| Last update posted | Aug 17, 2010 |
| Countries | Brazil, India, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: